Latest News About Devonian

Here’s a concise update on the latest Devonian-related news.

• Devonian Health Group Inc. (DVHGF/GSD) appears in several recent press releases and financial coverage, with activity spanning 2025 into early 2026, including study updates on Thykamine and corporate governance moves. This reflects ongoing preclinical and regulatory-related progress for their botanical drug programs. [cite ][cite ]

• In early 2026, Devonian announced positive preclinical results for Thykamine and filed a fingerprint related to their Thykamine platform, signaling momentum in their IP strategy and pipeline expansion. [cite ]

• The company has continued to publish quarterly results and strategic updates, including leadership appointments and financing activities, as part of communicating ongoing development and corporate governance to investors. [cite ][cite ]

• For the most current specifics (exact dates, trial stages, and numbers), you might check Devonian’s official press center and major financial news aggregators, as these platforms aggregate their latest releases and investor presentations. [cite ][cite ]

If you’d like, I can pull the latest individual press releases and summarize them with dates, key findings, and potential implications for their clinical programs.